Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

221. Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study

Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study 30253083 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study. 1461-1469 10.1111/1759-7714.12859 Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non-small (...) cell lung cancer (NSCLC), EGFR mutation testing is required. However, few studies have evaluated the extent of EGFR testing in real-world practice in China. A multicenter, observational study of EGFR testing in NSCLC patients in North China was conducted. Treatment-naïve patients or those with postoperative recurrent stage IIIB/IV NSCLC were enrolled. The primary objective was EGFR testing rate. Secondary objectives included EGFR mutation status, EGFR testing methods and specimens, factors

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

222. Optimizing Cervical Cancer Screening and Triage in Low-Resource Settings

Optimizing Cervical Cancer Screening and Triage in Low-Resource Settings 30252572 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Optimizing Cervical Cancer Screening and Triage in Low-Resource Settings. 1-2 10.1200/JGO.18.00192 Seay Julia S JS Julia S. Seay and Erin Kobetz, University of Miami School of Medicine, Miami, FL. Kobetz Erin E Julia S. Seay and Erin Kobetz, University of Miami School of Medicine, Miami, FL. eng Journal Article United States J Glob Oncol (...) 101674751 2378-9506 2018 9 26 6 0 2018 9 27 6 0 2018 9 27 6 0 ppublish 30252572 10.1200/JGO.18.00192 PMC6223538 BMC Cancer. 2011 Jun 13;11:239 21668946 J Low Genit Tract Dis. 2013 Jul;17(3):315-9 23422644 J Glob Oncol. 2018 Sep;(4):1-7 30241206 Obstet Gynecol Surv. 2012 Oct;67(10):658-67 23112073 Int J Gynecol Cancer. 2014 Mar;24(3):576-85 24557438 Cancer Causes Control. 1997 Sep;8(5):755-63 9328198 Clin Obstet Gynecol. 2013 Mar;56(1):76-87 23337844

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

223. Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality

Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality 30271878 2018 11 14 2379-5077 3 5 2018 Sep-Oct mSystems mSystems Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. e00081-18 10.1128/mSystems.00081-18 Epstein-Barr virus (EBV) is convincingly associated with gastric cancer, nasopharyngeal carcinoma, and certain lymphomas, but its role in other cancer types remains controversial. To test the hypothesis that there are additional cancer types with high prevalence (...) of EBV, we determined EBV viral expression in all the Cancer Genome Atlas Project (TCGA) mRNA sequencing (mRNA-seq) samples ( n = 10,396) from 32 different tumor types. We found that EBV was present in gastric adenocarcinoma and lymphoma, as expected, and was also present in >5% of samples in 10 additional tumor types. For most samples, EBV transcript levels were low, which suggests that EBV was likely present due to infected infiltrating B cells. In order to determine if there was a difference

mSystems2018 Full Text: Link to full Text with Trip Pro

224. Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer

Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer 30288475 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer. 1199-1212 10.1002/hep4.1204 While reactive ductules (RDs) have been observed in viral hepatitis, biliary atresia, nonalcoholic fatty liver disease, and adult hepatocellular carcinoma (HCC), RDs in (...) pediatric liver cancer remain uncharacterized. This study investigated the relationship of RDs with angiogenic paracrine factors, the extent of angiogenesis, and tumor cell proliferation in pediatric hepatoblastoma (HBL)/HCC livers. We quantified the extent of RDs and their expression of paracrine factors that include vascular endothelial growth factor (VEGF), vascular endothelial growth factor D (VEGFD), platelet-derived growth factor C, and angiopoietin 1 (ANGPT1). In addition, we performed

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

225. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.

Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. Importance: Variant reclassification is an important component of hereditary cancer genetic testing; however, there are few published data quantifying the prevalence of reclassification. Objective: Retrospective cohort study of individuals who had genetic testing from 2006 through 2016 at a single commercial laboratory. Design, Setting, and Participants: A retrospective cohort of individuals who had genetic (...) testing between 2006 and 2016 at a single commercial laboratory was assessed. Variants were classified as benign, likely benign, variant of uncertain significance, likely pathogenic, or pathogenic. Retrospective chart reviews were conducted for patients from the University of Texas Southwestern (UTSW) Medical Center. Exposures: Hereditary cancer genetic testing. Main Outcomes and Measures: Frequency of and time to amended reports; frequency and types of variant reclassification. Results: From 2006

JAMA2018

226. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. BACKGROUND: Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS: We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate (...) atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression

NEJM2018

227. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear. METHODS: In an open-label, phase 3 trial, we randomly

NEJM2018

228. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we (...) randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2

NEJM2018

229. Analysis of pharyngeal edema post‐chemoradiation for head and neck cancer: Impact on swallow function

Analysis of pharyngeal edema post‐chemoradiation for head and neck cancer: Impact on swallow function 30410991 2018 11 14 2378-8038 3 5 2018 Oct Laryngoscope investigative otolaryngology Laryngoscope Investig Otolaryngol Analysis of pharyngeal edema post-chemoradiation for head and neck cancer: Impact on swallow function. 377-383 10.1002/lio2.203 Edema is a frequent clinical observation following chemoradiation treatment (CRT) of oral/oropharyngeal cancer and is thought to contribute to post (...) -CRT swallowing impairment. Our aims were to reliably quantify pharyngeal edema pre- and post-CRT from videofluoroscopic (VF) swallowing studies and to explore the relationship between edema and swallowing impairment. Swallowing impairment was captured using patient-reported swallowing outcomes (EAT-10) and with VF confirmation of impairment (DIGEST). 40 patients (24 M, age 38-76) with oral/oropharyngeal cancer received radiotherapy (70 Gy, 7 weeks) and 3 weekly doses of cisplatin. VF and EAT-10

Laryngoscope investigative otolaryngology2018 Full Text: Link to full Text with Trip Pro

230. Androgen receptor expression in normal breast tissue and subsequent breast cancer risk

Androgen receptor expression in normal breast tissue and subsequent breast cancer risk 30276234 2018 11 29 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. 33 10.1038/s41523-018-0085-3 Sex steroid hormone signaling is critical in the development of breast cancers, although the role of the androgen receptor remains unclear. This study evaluated androgen receptor (AR) expression in normal breast tissue (...) as a potential marker of breast cancer risk. We conducted a nested case-control study of women with benign breast disease (BBD) within the Nurses' Health Studies. Epithelial AR expression was assessed by immunohistochemistry in normal tissue from the BBD biopsy and the percent of positive nuclei was estimated in ordinal categories of 10% for 78 breast cancer cases and 276 controls. Logistic regression models adjusting for the matching factors and BBD lesion type were used to calculate odds ratios (ORs

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

231. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.

Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. BACKGROUND: Olanzapine as an antiemetic represents a new use of an antipsychotic drug. People with cancer may experience nausea and vomiting whilst receiving chemotherapy or radiotherapy, or whilst in the palliative phase of illness. OBJECTIVES: To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults (...) or vomiting in people with cancer aged 18 years or older, in any setting, of any duration, with at least 10 participants per treatment arm. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodology. We used GRADE to assess quality of evidence for each main outcome. We extracted data for absence of nausea or vomiting and frequency of serious adverse events as primary outcomes. We extracted data for patient perception of treatment, other adverse events, somnolence and fatigue, attrition, nausea

Cochrane2018

232. Interventions for promoting habitual exercise in people living with and beyond cancer.

Interventions for promoting habitual exercise in people living with and beyond cancer. BACKGROUND: This is an updated version of the original Cochrane Review published in the Cochrane Liibrary 2013, Issue 9. Despite good evidence for the health benefits of regular exercise for people living with or beyond cancer, understanding how to promote sustainable exercise behaviour change in sedentary cancer survivors, particularly over the long term, is not as well understood. A large majority of people (...) living with or recovering from cancer do not meet current exercise recommendations. Hence, reviewing the evidence on how to promote and sustain exercise behaviour is important for understanding the most effective strategies to ensure benefit in the patient population and identify research gaps. OBJECTIVES: To assess the effects of interventions designed to promote exercise behaviour in sedentary people living with and beyond cancer and to address the following secondary questions: Which interventions

Cochrane2018

233. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study. Background: The fecal immunochemical test (FIT) is commonly used for colorectal cancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex. Objective: To identify programmatic (multitest) FIT performance characteristics and optimal FIT quantitative (...) hemoglobin positivity thresholds in a large, population-based, screening program. Design: Retrospective cohort study. Setting: Kaiser Permanente Northern and Southern California. Participants: Adults aged 50 to 75 years who were eligible for screening and had baseline quantitative FIT results (2013 to 2014) and 2 years of follow-up. Nearly two thirds (411 241) had FIT screening in the previous 2 years. Measurements: FIT programmatic sensitivity for CRC and number of positive test results per cancer case

Annals of Internal Medicine2018

234. Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China

Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China 30296013 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China. 1565-1572 10.1111/1759 (...) -7714.12852 Prognostic assessment after preoperative systemic therapy (PST) is critical to develop a therapeutic strategy for breast cancer management. Currently, a clinical-pathologic staging system that incorporates ER status and nuclear grading (CPS + EG), and the Neo-Bioscore system that includes HER2 status into CPS + EG, are used to predict outcomes in patients with breast cancer after PST. While HER2-positive is recognized as a favorable factor in the Neo-Bioscore system based on results

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

235. Resection for hepatocellular cancer: overpassing old barriers

Resection for hepatocellular cancer: overpassing old barriers 30363682 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Resection for hepatocellular cancer: overpassing old barriers. 64 10.21037/tgh.2018.09.13 Several recent studies have shown that the selection limits commonly used for patients with hepatocellular cancer (HCC) potentially requiring a liver resection (LR) are too restrictive. The present review aims at investigating (...) Hepatol 101683450 2415-1289 Barcelona Clinic Liver Cancer (BCLC) Portal hypertension (PHT) liver failure mini-invasive surgery model for end-stage liver disease (MELD) Conflicts of Interest: The authors have no conflicts of interest to declare. 2018 08 23 2018 09 11 2018 10 27 6 0 2018 10 27 6 0 2018 10 27 6 1 epublish 30363682 10.21037/tgh.2018.09.13 tgh-03-2018.09.13 PMC6182022 JAMA Surg. 2014 Sep;149(9):941-6 25075581 Gastroenterology. 2008 Jun;134(7):1908-16 18549877 PLoS One. 2013 Jul 09;8(7

Translational gastroenterology and hepatology2018 Full Text: Link to full Text with Trip Pro

236. Recent advances in colorectal cancer screening

Recent advances in colorectal cancer screening 30276360 2018 11 14 2589-0514 4 3 2018 Sep Chronic diseases and translational medicine Chronic Dis Transl Med Recent advances in colorectal cancer screening. 139-147 10.1016/j.cdtm.2018.08.004 Li Dan D Department of Gastroenterology, Kaiser Permanente Medical Center, Santa Clara, CA 95051, USA. Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA. eng Editorial 2018 09 17 China Chronic Dis Transl Med 101679934 2095 (...) -882X Colonoscopy Colorectal cancer Screening 2018 06 26 2018 10 3 6 0 2018 10 3 6 0 2018 10 3 6 1 epublish 30276360 10.1016/j.cdtm.2018.08.004 S2095-882X(18)30060-4 PMC6160607 Lancet. 2013 Apr 6;381(9873):1185-93 23414648 Am J Surg Pathol. 2004 Nov;28(11):1452-9 15489648 Gastroenterology. 2016 Nov;151(5):870-878.e3 27443823 CA Cancer J Clin. 2017 May 6;67(3):177-193 28248415 Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7 26226577 Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330

Chronic diseases and translational medicine2018 Full Text: Link to full Text with Trip Pro

237. Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies.

Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies. BACKGROUND: Estimates of survival for women diagnosed with early staged breast cancer are available based on stratification into prognostic categories defined using the Nottingham Prognostic Index (NPI). This review aimed to identify and summarize the estimated survival statistics from separate sources in the literature and to explore (...) the extent of between-study heterogeneity in survival estimates. METHODS: Observational studies in women diagnosed with early and locally advanced breast cancer reporting overall survival by NPI category were identified using a systematic literature search. An exploratory meta-analysis was conducted to describe survival estimates and assess between-study heterogeneity. RESULTS: Twenty-eight studies were identified. Nineteen studies with sufficient data on overall survival were included in meta-analysis

Systematic Reviews2018 Full Text: Link to full Text with Trip Pro

238. Transplantation for hepatocellular cancer: pushing to the limits?

Transplantation for hepatocellular cancer: pushing to the limits? 30363754 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Transplantation for hepatocellular cancer: pushing to the limits? 61 10.21037/tgh.2018.09.07 Milan criteria (MC) represents the cornerstone in the selection of patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT). MC represent the precursor of the scores based on the idea of "utility (...) ": in other terms, the scoring systems typically used in the field of LT oncology present the exclusive aim of selecting the cases with the best post-LT outcomes. However, some other scores have been proposed specifically investigating the risk of death or tumour progression during the waiting list. In this case, the selection process is connected with the idea of "priority": patients at higher risk for drop-out (DO) should be selected, prioritising them or, conversely, deciding to de-list them due

Translational gastroenterology and hepatology2018 Full Text: Link to full Text with Trip Pro

239. Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer

Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer 30209884 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer. 1483-1491 10.1111/1759-7714.12862 The importance of nutritional status and chronic inflammation has been emphasized in cancer. We investigated the impact of Onodera's prognostic nutritional index (OPNI) on clinical (...) outcomes in small cell lung cancer (SCLC) patients. Data from 220 SCLC patients treated with first-line platinum-based chemotherapy from 2006 to 2017 were retrospectively reviewed. The OPNI was calculated as 10 × serum albumin level (g/dL) + 0.005 × absolute lymphocyte count (/mm 3 ). Patients with an OPNI of > 45, 40-45, or < 40 were categorized in high, intermediate, or low OPNI groups, respectively. The proportion of non-responders to first-line therapy increased as the OPNI decreased (high

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

240. Resection for intrahepatic cholangiocellular cancer: new advances

Resection for intrahepatic cholangiocellular cancer: new advances 30363713 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Resection for intrahepatic cholangiocellular cancer: new advances. 60 10.21037/tgh.2018.08.03 Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent primary liver neoplasm after hepatocellular carcinoma (HCC), corresponding to 10% to 15% of cases. Pathologies that cause chronic biliary inflammation (...) and bile stasis are known predisposing factors for development of ICC. The incidence and cancer-related mortality of ICC is increasing worldwide. Most patients remain asymptomatic until advance stage, commonly presenting with a liver mass incidentally diagnosed. The only potentially curative treatment available for ICC is surgical resection. The prognosis is dismal for unresectable cases. The principle of the surgical approach is a margin negative hepatic resection with preservation of adequate liver remnant

Translational gastroenterology and hepatology2018 Full Text: Link to full Text with Trip Pro